{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T11:10:03Z","timestamp":1756293003549,"version":"3.44.0"},"reference-count":29,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2021,5,14]]},"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:p>A man in his early 40s with no significant vascular risk factors was managed within a period of 6 months for recurrent vascular events: ischaemic stroke, transient ischaemic attack and isolated third nerve palsy. He was extensively investigated throughout the course of illness. The only potential aetiological factor identified was a positive janus kinase 2 (JAK 2) mutation after screening on account of mildly elevated platelet count noted during his most recent admission. Bone marrow aspiration confirmed essential thrombocythaemia. He was started on hydroxycarbamide and has remained relatively symptom free since then.<\/jats:p>\n               <jats:p>This case reiterates the known associations between thrombosis and JAK 2 mutation even without overt myeloproliferative neoplasms. It also highlights the need for specialists in stroke to consider screening for JAK 2 mutation in a young patient with cryptogenic stroke with or without polycythemia or thrombocytosis.<\/jats:p>","DOI":"10.1136\/bcr-2021-242270","type":"journal-article","created":{"date-parts":[[2021,6,10]],"date-time":"2021-06-10T13:12:13Z","timestamp":1623330733000},"page":"e242270","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":3,"title":["JAK 2 positive myeloproliferative neoplasm presenting as stroke, recurrent TIA and isolated third nerve palsy"],"prefix":"10.1136","volume":"14","author":[{"given":"Paul","family":"Bolaji","sequence":"first","affiliation":[{"name":"Stroke Medicine, New Cross Hospital, Wolverhampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saugata","family":"Das","sequence":"additional","affiliation":[{"name":"Stroke Medicine, New Cross Hospital, Wolverhampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nasar","family":"Ahmad","sequence":"additional","affiliation":[{"name":"Stroke Medicine, New Cross Hospital, Wolverhampton, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2021,6,10]]},"reference":[{"key":"2025082703333674000_14.6.e242270.1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-460154"},{"key":"2025082703333674000_14.6.e242270.2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2010.038299"},{"key":"2025082703333674000_14.6.e242270.3","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP7VO4HAIZYATP"},{"key":"2025082703333674000_14.6.e242270.4","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02616.x"},{"key":"2025082703333674000_14.6.e242270.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2013.04.009"},{"key":"2025082703333674000_14.6.e242270.6","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1016\/j.jstrokecerebrovasdis.2018.05.052","article-title":"Implications of Janus kinase 2 mutation in embolic stroke of unknown source","volume":"27","author":"Trifan","year":"2018","journal-title":"J Stroke Cerebrovasc Dis"},{"key":"2025082703333674000_14.6.e242270.7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181f612ce"},{"key":"2025082703333674000_14.6.e242270.8","doi-asserted-by":"publisher","DOI":"10.1177\/155989771301007"},{"key":"2025082703333674000_14.6.e242270.9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1016\/j.amjcard.2015.06.012","article-title":"A comparison of atrial fibrillation monitoring strategies after cryptogenic stroke (from the cryptogenic stroke and underlying AF trial)","volume":"116","author":"Choe","year":"2015","journal-title":"Am J Cardiol"},{"key":"2025082703333674000_14.6.e242270.10","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1212\/WNL.0000000000008894","article-title":"Teaching NeuroImages: stroke presenting with isolated superior branch of cranial nerve III palsy","volume":"94","author":"Kapoor","year":"2020","journal-title":"Neurology"},{"key":"2025082703333674000_14.6.e242270.11","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.jocn.2011.05.023","article-title":"Oculomotor nerve palsy as an initial manifestation of polycythemia vera","volume":"19","author":"Park","year":"2012","journal-title":"J Clin Neurosci"},{"key":"2025082703333674000_14.6.e242270.12","doi-asserted-by":"crossref","first-page":"e85","DOI":"10.1212\/WNL.0000000000001927","article-title":"Pearls & Oy-sters: An isolated cranial nerve 6 palsy as a presentation of polycythemia vera","volume":"85","author":"Ahlawat","year":"2015","journal-title":"Neurology"},{"key":"2025082703333674000_14.6.e242270.13","doi-asserted-by":"crossref","first-page":"362","DOI":"10.3928\/0191-3913-19781101-06","article-title":"Acquired \"double elevator\" palsy and polycythemia vera","volume":"15","author":"Hoyt","year":"1978","journal-title":"J Pediatr Ophthalmol Strabismus"},{"key":"2025082703333674000_14.6.e242270.14","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.46.9.873"},{"key":"2025082703333674000_14.6.e242270.15","first-page":"421","article-title":"Myeloproliferative disorders--neurological complications","volume":"6","author":"Tarach","year":"2000","journal-title":"Med Sci Monit"},{"key":"2025082703333674000_14.6.e242270.16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1159\/000084372","article-title":"Subarachnoid hemorrhage and diplopia as initial presentation of polycythemia vera","volume":"19","author":"Opherk","year":"2005","journal-title":"Cerebrovasc Dis"},{"key":"2025082703333674000_14.6.e242270.17","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1055\/s-0039-1693477","article-title":"Pathogenesis and management of thrombotic disease in myeloproliferative neoplasms","volume":"45","author":"Arachchillage","year":"2019","journal-title":"Semin Thromb Hemost"},{"key":"2025082703333674000_14.6.e242270.18","first-page":"178","article-title":"Prevention and management of thrombosis in myeloproliferative neoplasms","volume":"15","author":"Sekhar","year":"2017","journal-title":"Clin Adv Hematol Oncol"},{"key":"2025082703333674000_14.6.e242270.19","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-976165"},{"key":"2025082703333674000_14.6.e242270.20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000360388","article-title":"Aspirin-responsive, migraine-like transient cerebral and ocular ischemic attacks and erythromelalgia in JAK2-positive essential thrombocythemia and polycythemia vera","volume":"133","author":"Michiels","year":"2015","journal-title":"Acta Haematol"},{"key":"2025082703333674000_14.6.e242270.21","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-08-042515"},{"key":"2025082703333674000_14.6.e242270.22","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-07-591610"},{"key":"2025082703333674000_14.6.e242270.23","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.neurol.2016.09.010","article-title":"Cerebrovascular events as presenting manifestations of myeloproliferative neoplasm","volume":"172","author":"Ong","year":"2016","journal-title":"Rev Neurol"},{"key":"2025082703333674000_14.6.e242270.24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-460154"},{"key":"2025082703333674000_14.6.e242270.25","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1111\/ene.13907","article-title":"Recurrent ischaemic cerebrovascular events as presenting manifestations of myeloproliferative neoplasms","volume":"26","author":"Stefanou","year":"2019","journal-title":"Eur J Neurol"},{"key":"2025082703333674000_14.6.e242270.26","unstructured":"Xhani R , Fumagalli L , Appollonio I . JAK2 mutation in embolic stroke of unknown source. In: ESOC-2019. Morressier, 2020. https:\/\/www.morressier.com\/article\/jak2-mutation-embolic-stroke-unknown-source\/5cb58ceec668520010b562fd"},{"key":"2025082703333674000_14.6.e242270.27","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.5858\/2006-130-1126-PV","article-title":"Polycythemia vera: new clinicopathologic perspectives","volume":"130","author":"Cao","year":"2006","journal-title":"Arch Pathol Lab Med"},{"key":"2025082703333674000_14.6.e242270.28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-501452"},{"key":"2025082703333674000_14.6.e242270.29","first-page":"169","article-title":"Increased platelet and leukocyte activation as contributing mechanisms for thrombosis in essential thrombocythemia and correlation with the JAK2 mutational status","volume":"91","author":"Arellano-Rodrigo","year":"2006","journal-title":"Haematologica"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2021-242270","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T10:33:44Z","timestamp":1756290824000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2021-242270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,6,10]]},"published-print":{"date-parts":[[2021,6]]}},"alternative-id":["10.1136\/bcr-2021-242270"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2021-242270","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}